Drug Type Monoclonal antibody |
Synonyms anti-RANK-L mAb (Suzhou AlphaMab), KN-013 |
Target |
Action modulators |
Mechanism NFKB1 modulators(nuclear factor kappa B subunit 1 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone metastases | Discovery | China | - |